TABLE 4

Clinical and inflammatory characteristics of participants with and without Tropheryma sequences

Tropheryma presentTropheryma absentp-value
Subjects723
Age years53±1460±90.175
Male2 (29)10 (43)0.403
Atopic5 (71)19 (87)0.347
Ex-smoker4 (57)12 (52)0.581
Smoking pack-years16.7 (7.7, 47.8)14.4 (1.3, 40.3)0.505
FEV1 % predicted81±2476±150.577
FEV1/FVC %71±1068±100.517
ICS dose µg2000 (2000, 4000)2000 (1000, 2000)0.150
ACQ6 score1.0±0.71.5±1.00.250
VAS symptom scores
 Breathlessness6.5 (2.1, 23.0)7.0 (4.1, 10.0)1.000
 Wheeze3.5 (1.0, 4.6)3.2 (0.8, 6.7)0.683
 Cough6.0 (3.7, 7.2)7.4 (2.2, 10.0)0.386
 Sputum production3.8 (0.0, 5.9)4.7 (1.8, 10.0)0.740
Inflammatory cell counts
 Total cell count ×106 mL–15.2 (3.3, 7.2)4.6 (2.2, 8.9)0.713
 Viability %85 (74, 94)81 (75, 84)0.328
 Neutrophils %40.9±25.541.8±25.70.942
 Eosinophils %1.8 (1.0, 7.0)1.5 (0.3, 4.0)0.769
 Macrophages %45 (35, 77)41 (21, 61)0.419
 Lymphocytes %1.0 (0.3, 2.5)0.5 (0.3, 1.0)0.457
 Columnar epithelial cells %0.5 (0.3, 2.5)1.3 (0.3, 3.0)0.475
 Squamous cells %6.8 (1.5, 9.5)3.6 (0.5, 6.3)0.154
  • Data are presented as n, mean±sd, n (%) or median (quartile 1, quartile 3), unless otherwise stated. FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; ACQ6: Asthma Control Questionnaire 6; ICS: inhaled corticosteroid; VAS: visual analogue scale.